DAX24.241 +0,8%ESt505.344 +1,0%Top 10 Crypto15,45 -6,3%Dow44.988 +1,1%Nas21.010 +0,6%Bitcoin100.560 -1,6%Euro1,1772 +0,2%Öl68,73 +0,1%Gold3.391 -1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SAP 716460 NVIDIA 918422 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 BASF BASF11 Clara Technologies A3E4MS BYD A0M4W9 Volkswagen (VW) vz. 766403 Novo Nordisk A3EU6F Tesla A1CX3T Deutsche Bank 514000 Infineon 623100 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zoll-Deal mit Japan: DAX schließt höher -- US-Börsen fester - S&P 500 mit Rekord -- SAP mit Gewinnsprung - Umsatz unter Erwartungen -- D-Wave, Infineon, TUI, Micron, Clara Technologies, Tesla im Fokus
Top News
Zoll-Deal mit EU in Sicht? US-Aktienmärkte verbuchen Gewinne - S&P 500 mit neuem Allzeithoch Zoll-Deal mit EU in Sicht? US-Aktienmärkte verbuchen Gewinne - S&P 500 mit neuem Allzeithoch
Dürr-Aktie tiefer: Verhaltener Auftragseingang - Ausblick für 2025 angepasst Dürr-Aktie tiefer: Verhaltener Auftragseingang - Ausblick für 2025 angepasst
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Bitcoin: Der Pfad zur 1-Million-Dollar-Marke - und wie Anleger davon profitieren

IDEAYA Biosciences Aktie

Handeln
Aktien-Sparplan anlegen
18,70 EUR +0,20 EUR +1,08 %
FSE
23,63 USD +1,59 USD +7,21 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.1,64 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PJPB

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS45166A1025

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIDYA

IDEAYA Biosciences Aktien News

DatumMeistgelesen
PR NewswireIDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
PR NewswireIDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
PR NewswireIDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
Wer­bungIDEAYA Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
PR NewswireIDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
PR NewswireIDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
PR NewswireIDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
PR NewswireIDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
PR NewswireIDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
PR NewswireIDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
PR NewswireIDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
PR NewswireIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
PR NewswireIDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
PR NewswireIDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
PR NewswireIDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
PR NewswireIDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
PR NewswireIDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
PR Newswire/C O R R E C T I O N -- IDEAYA Biosciences, Inc./
PR NewswireIDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences News

IDEAYA Biosciences News: auf dieser Seite finden Sie alle IDEAYA Biosciences News und Nachrichten zur IDEAYA Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch IDEAYA Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um IDEAYA Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.